AbbVie’s Skyrizi gains pediatric psoriatic disease indication
The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or ...
Sunday, August 16, 2026
Tag: Skyrizi
Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.